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by DA. Indirect pathway neurons preferentially project to the exter-
nal segment of the globus pallidus and inhibit movement when 
activated (Smith et al., 1998; Kravitz et al., 2010). They express 
D2 receptors that attenuate synaptic activity when stimulated by 
DA. Thus, direct and indirect pathways have opposite effects on 
movement and express DA receptors that have opposite effects on 
cell excitability.
Medium-sized spiny neurons are driven by two main gluta-
matergic inputs, those from cortex and thalamus. Intrastriatal 
inputs from GABAergic interneurons and axon collaterals from 
other MSNs provide feedforward and feedback inhibition, respec-
tively. DA also exerts control of neurotransmitter release by directly 
activating presynaptic D2 receptors present on many terminals in 
the striatum or indirectly by interacting with other endogenous 
modulators (Malenka and Kocsis, 1988; Lovinger, 2008). In HD, 
glutamate and DA transmission are altered, which likely produces 
an imbalance in the activity of the direct and indirect pathways 
and contributes to the motor, cognitive, and psychiatric symptoms 
of HD.
Huntington’s disease is a neurodegenerative disease character-
ized by a progression of motor symptoms manifesting as chorea in 
early stages and as akinesia in later stages (Thompson et al., 1988). 
IntroductIon
Huntington’s disease (HD) is caused by the mutation of a gene 
inducing expansion of CAG triplets on the huntingtin (htt) protein 
(The Huntington’s Disease Collaborative Research Group, 1993). 
In HD, the most obvious neuropathology is observed in the cortex 
and in the striatum. More specifically, striatal medium-sized spiny 
neurons (MSNs) expressing enkephalin and dopamine (DA) D2 
receptors, forming the indirect pathway, are believed to be the most 
vulnerable and are preferentially lost in brains of presymptomatic 
and fully symptomatic patients. In contrast, MSNs expressing sub-
stance P and D1 receptors, forming the direct pathway, are believed 
to be relatively spared early in the progression of the disorder 
(Vonsattel et al., 1985; Albin et al., 1990).
The earlier vulnerability of indirect pathway MSNs in HD could 
induce imbalances in striatal output to other basal ganglia nuclei, 
which will affect the final outflow to the thalamus and contribute 
to the motor disturbances in the disease. Direct pathway MSNs 
preferentially project to the substantia nigra pars reticulata and to 
the internal segment of the globus pallidus (Gerfen, 1992; Bolam 
et al., 2000) and facilitate movement when activated (Chevalier 
et al., 1985a,b). In addition, direct pathway MSNs express high levels 
of DA D1 receptors that enhance synaptic activity when stimulated 
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way activity would be different at early and late stages of the disease. 
We examined the YAC128 (yeast artificial chromosome) mouse 
model of HD at an early symptomatic stage (1.5 months) and a 
symptomatic stage (12 months). YAC mice with 128 CAG repeats 
show a biphasic motor phenotype with hyperactivity at 3 months 
followed by hypoactivity in the open field at 12 months. Modest 
striatal atrophy occurs at 9 months and a small but significant 
decrease in striatal neurons is evident at 12 months (Slow et al., 
2003). We also examined the BACHD (bacterial artificial chromo-
some) model at an early symptomatic stage (2 months). BACHD 
mice express human mutant HTT with 97 CAG repeats and exhibit 
progressive motor deficits starting at 2 months, followed by late-
onset selective neuropathology at 12 months (Gray et al., 2008). 
BAC and YAC transgenics are used to permit expression of the 
full-length human mutant HTT, in order to reproduce more faith-
fully the human condition. BACHD and YAC128 mice develop 
a more protracted and progressive phenotype than the fragment 
models such as the R6/2, recapitulating the juvenile form of the 
disease (Mangiarini et al., 1996; Schilling et al., 1999). Full-length 
models of HD allow the investigation at an early stage of the dis-
ease, when symptoms start to develop while it is more difficult 
to separate time-dependent changes in fragment models showing 
rapid and aggressive progression of the disease. They also present 
more robust motor deficits and neuropathology than the knock-in 
models (Shelbourne et al., 1999; Wheeler et al., 2000). Although 
BAC and YAC transgenes allow the expression of large genomic 
sequence, they display a limited neuronal loss (10–15%) and do 
not recapitulate a shorter lifespan, as seen in the human condition 
(Tang et al., 2007).
To assess functional activity of specifically identified neurons, we 
crossed YAC128 or BACHD mice with mice expressing a reporter 
gene under the control of the promoter for either DA D1 or D2 
receptors. In the double transgenic mice we examined excitatory 
and inhibitory postsynaptic currents (EPSCs and IPSCs) and DA 
modulation in direct and indirect pathway MSNs. As tetrabenazine 
(TBZ) is the only drug providing significant benefit in the treat-
ment of chorea associated with HD, we also tested the effect of this 
monoamine-depleting agent in vitro and in vivo. Portions of this 
study were published previously (André et al., 2011).
MaterIals and Methods
anIMals
All experimental procedures were performed in accordance with 
the United States Public Health Service Guide for Care and Use 
of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the University of California 
Los Angeles (UCLA). Every effort was made to minimize pain and 
discomfort. Experiments were conducted in two mouse models of 
adult-onset HD crossbred to heterozygous FVB/N mice express-
ing enhanced green fluorescent protein (EGFP) under the control 
of the promoter for dopamine receptor D1 or D2, obtained from 
our colony at UCLA. One mouse model carried full-length human 
mutant HTT, including 128 CAG repeats, on a yeast artificial chro-
mosome (YAC128, line 53; Slow et al., 2003). YAC128 and WT 
littermates expressing D1- or D2-EGFP were obtained from our 
colonies at UCLA at 1.5 and 12 months of age. The second mouse 
model carried full-length human mutant HHT, including 97 CAG 
repeats, on a bacterial artificial chromosome (BACHD; Gray et al., 
2008). BACHD and WT littermates expressing D1- or D2-EGFP at 
2 months of age were also obtained from our colonies.
cell VIsualIzatIon
Enhanced green fluorescent protein-positive cells were visualized in 
slices using a 40× water immersion lens. The microscope (Olympus 
BX50WI or Zeiss Axioscope) was equipped with differential inter-
ference contrast optics and fluorescence. For infrared videomicros-
copy, a halogen lamp and an infrared filter (790 nm, Ealing Optics, 
Holliston, MA, USA) were used. For fluorescence, ultra-violet light 
was filtered to obtain 480 nm excitation light. The light source con-
sisted of a mercury lamp (100 W) and fluorescent light was detected 
with a video camera (QICAM-IR Fast 1394, Burnaby, BC, Canada) 
optimized to detect EGFP fluorescence and infrared light. Images 
were digitized and saved using the Q Capture Pro software (version 
5, Burnaby, BC, Canada). Once a viable MSN was identified with 
infrared videomicroscopy, the filter was switched to fluorescence 
to determine if it was labeled with EGFP. The digitized infrared 
image was superimposed over the fluorescence image, and electro-
physiological recordings proceeded only if the cell identified with 
infrared light showed a complete overlap with EGFP fluorescence.
experIMents In slIces
Detailed procedures have been published (Cepeda et al., 1993; 
André et al., 2010). Briefly, mice were deeply anesthetized with 
halothane and sacrificed. The brains were dissected and imme-
diately placed in oxygenated ice-cold low-Ca2+ artificial cerebro-
spinal fluid (ACSF) containing (in millimolar); NaCl, 130; KCl, 3; 
NaH2PO4, 1.25; NaHCO3, 26; MgCl2, 5; CaCl2, 1; and glucose, 10. 
Coronal slices (350 μm) were cut and transferred to an incubating 
chamber containing ACSF (with 2 mM CaCl2 and 2 mM MgCl2) 
oxygenated with 95% O
2
− 5% CO2 (pH 7.2–7.4, 290–310 mOsm, 
25 ± 2°C). Slices were visualized and EGFP-expressing cells were 
selected for recordings. The patch pipette contained (in millimo-
lar): Cs-methanesulfonate 130, CsCl 10, NaCl 4, MgCl2 1, MgATP 
5, EGTA 5, HEPES 10, GTP 0.5, phosphocreatine 10, leupeptin 
0.1 for voltage clamp recordings. Access resistances were <20 MΩ. 
Spontaneous postsynaptic currents were recorded in standard 
ACSF at room temperature. Membrane current was filtered at 1 kHz 
and digitized at 100–200 μs using Clampex 10.2 (gap-free mode). 
Cells were voltage clamped at −70 mV to determine basic mem-
brane properties and to examine spontaneous glutamate receptor-
mediated EPSCs. Bicuculline methiodide (Bic, 10 μM) was applied 
in order to block GABAA receptor-mediated currents. For IPSCs, 
voltage was held at +10 mV. For experiments examining the modu-
lation of GABA receptor-mediated currents, AMPA and NMDA 
receptor blockers 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]
quinoxaline-7-sulfonamide (NBQX) and d-(−)-2-amino-5-
phosphonopentanoic acid (APV), respectively were added. Baseline 
activity was recorded for 3–5 min after a 10- to 15-min baseline 
and another 5–10 min after addition of D1 or D2 receptor agonists 
(SKF81297 or quinpirole, 5–10 μM). To evoke synaptic currents, 
a monopolar glass stimulating electrode (patch pipette filled with 
ACSF, impedance 1.5–1.8 MΩ) was placed in the corpus callosum, 
200–300 μm from the recorded cell. 
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1999) and subsequently checked manually for accuracy. Event anal-
yses were done blind to genotype. The threshold amplitude for the 
detection of an excitatory event (5 pA) was set above the root mean 
square background noise level (1–2 pA at Vhold = −70 mV). For 
inhibitory events, the detection was set at 10 pA because the noise 
level was higher (2–3 pA at Vhold = −10 mV). Amplitude–frequency 
and cumulative inter-event interval distributions were constructed 
and compared among the different groups using two-way repeated 
measures (RM) ANOVAs to compare events at each amplitude and 
interval, followed by Bonferroni t-tests (multiple group compari-
sons) using SigmaStat software (SPSS, Chicago, IL, USA).
results
GlutaMate transMIssIon and GaBa transMIssIons In d1-
Yac128 cells
At 1.5 months, D1-YAC128 cells displayed a higher frequency 
of spontaneous excitatory postsynaptic currents (sEPSCs) than 
D1-WT cells (t38 = 2.65, p = 0.012) while at 12 months, this differ-
ence was reversed (t29 = 3.24, p = 0.003; Figures 1A,B). Cumulative 
inter-event interval histograms also showed a significantly increased 
probability of release onto D1-YAC128 cells at the early stage, while 
at 12 months, they showed a decreased probability of glutamate 
release onto D1-YAC128 cells (Figure 1C).
D1-YAC128 also displayed a higher frequency of sIPSCs at 
1.5 months (t47 = 2.36, p = 0.022) while there was no difference at 
12 months (t29 = 1.44, p = 0.161, Figures 1D,E). Cumulative inter-
event interval histograms for IPSCs also showed a significantly 
increased probability of GABA release onto D1-YAC128 cells at 
1.5 months but not at 12 months (Figure 1F).
GlutaMate transMIssIon and GaBa transMIssIon In d2-Yac128 
cells
In contrast to the D1 cells, D2-YAC128 cells did not show any 
significant differences in mean sEPSCs at 1.5 (t37 = 0.86, p = 0.395) 
or at 12 months (t31 = 1.083, p = 0.287, Figures 2A,B). Cumulative 
inter-event interval histograms did not show any differences at 
1.5 months but at 12 months, the significant rightward shift sug-
gests a decrease of glutamate release in late stage D2-YAC128 cells 
(Figure 2C).
In 1.5 month D2 cells, there was no difference in the mean IPSC 
frequency (t40 = 0.693, p = 0.492) or the inter-event interval his-
togram (Figures 2D–F). However, at 12 months, IPSC frequency 
was increased (t27 = 2.668, p = 0.013) in the D2-YAC128 cells and 
the cumulative inter-event interval histogram suggested increased 
probability of GABA release onto D2-YAC128 cells (Figures 2E,F).
GlutaMate transMIssIon and GaBa transMIssIon are 
Increased In d1 cells In Bachd MIce at 2 Months
Similar to D1-YAC128 cells, D1-BACHD cells displayed a higher 
sEPSC frequency at 2 months (t18 = 2.781, p = 0.012, Figure 3A). 
To provide further evidence that the differences in EPSC frequen-
cies were due to altered glutamate release, we examined responses 
evoked by stimulation of corticostriatal afferents (eEPSCs) and 
measured PPRs (André et al., 2011). At 2 months, D1-BACHD 
cells displayed a significant decrease in PPRs (two-way RM ANOVA 
F1,89 = 15.6, p = 0.001) at 25 (t = 3.8, p < 0.001) and 50 (t = 3.57, 
Test-stimuli (500 μs   duration) were applied every 20 s and aver-
aged over three consecutive trials. Stimulation intensities were set 
to evoke responses at 30% maximal amplitude. Paired-pulse ratios 
(PPRs) were used to assess probability of release, and paired-pulses 
were applied at intervals between 25 and 400 ms.
druGs
Stocks of Bic (20 mM, Tocris), D1 receptor agonist SKF81297 
(1 mM, Sigma), D2 receptor agonist quinpirole (10 mM, Sigma) 
were all dissolved in H2O. TBZ (10 mM, Tocris) was dissolved in 
100% DMSO for stock solution and final concentration for elec-
trophysiology was 0.1%. For in vivo injections, TBZ (1 mg/ml) 
was dissolved in a mixture of DMSO/NaCl (50/50). Procedures 
for determination of the appropriate TBZ dosage in vivo have been 
published (André et al., 2011).
acutelY dIssocIated neurons
Detailed procedures have been published (Flores-Hernandez et al., 
2002). Briefly, coronal slices containing the dorsal striatum were 
dissected, placed in an oxygenated cell-stir chamber (Wheaton, 
Millville, NJ, USA) and enzymatically treated for 15–20 min with 
papain (0.5 mg/ml, Calbiochem) at 35°C in a N-[2-hydroxyethyl] 
piperazine-N-[2-ethanesulfonic acid] (HEPES)-buffered Hank’s 
balanced salts solution (HBSS, Sigma Chemical) supplemented 
with (in millimolar) 1 pyruvic acid, 0.005 glutathione, 0.1 
NG-nitro-l-arginine, and 1 kynurenic acid. The tissue was rinsed 
with HEPES-buffered Na-isethionate solution containing (in mil-
limolar) 140 Na isethionate, 2 KCl, 2 MgCl2, 0.1 CaCl2, 23 glucose, 
and 15 HEPES. Striatal slices were mechanically dissociated with 
fire-polished Pasteur pipettes. The cell suspension was then plated 
into a 35-mm Petri dish mounted on the stage of an upright fixed-
stage microscope containing a HEPES-buffered salt solution. Only 
fluorescent cells were selected for recordings.
The internal solution consisted of (in millimolar) 175 N-methyl-
d-glucamine (NMDG), 40 HEPES, 2 MgCl2, 10 ethylene glycol-
bis (β-aminoethyl ether)-N,N,N′,N′-tetra-acetic acid (EGTA), 
12 phosphocreatine, 2 Na2ATP, 0.2 Na2GTP, and 0.1 leupeptin 
(pH 7.25, 265–270 mOsm). The external solution consisted of 
(in millimolar) 135 NaCl, 20 CsCl, 3 BaCl2, 2 CaCl2, 10 glucose, 
10 HEPES, and 0.0003 tetrodotoxin (TTX). Drugs were applied 
through a pressure-driven fast perfusion system using application 
capillaries positioned a few hundred micrometers from the cell. A 
DC drive system controlled by a SF-77B perfusion system (Warner 
Instruments, Hamden, CT, USA) synchronized by pClamp changed 
solutions by altering the position of the capillary array. NMDA 
currents (100 μM, 3 s duration every 10 s) were evoked by applying 
the agonist while holding the cell at −70 mV. D1 and D2 agonists 
were applied as previously described (André et al., 2010).
data analYsIs and statIstIcs
In the text, values are presented as mean ± SEM. Data analyses were 
performed with Origin (Microcal Software, Northampton, MA, 
USA) and pClamp 10.2. Group means for all measures were com-
pared using Student’s t-tests (for two group comparisons) using 
SigmaStat software (SPSS, Chicago, IL, USA). Differences were con-
sidered statistically significant when p < 0.05. Spontaneous synap-
tic currents were analyzed offline using the automatic detection 
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transported to the surface and functional, we tested the effects of 
D1 and D2 agonists on postsynaptic NMDA currents in acutely 
dissociated D1 and D2 MSNs at 1.5 months. It is well known that 
D1 receptor activation increases NMDA currents while D2 receptor 
activation decreases them (Cepeda et al., 1993; André et al., 2010). 
The D1 agonist (SKF81297, 1 μM) increased NMDA currents in 
D1 cells similarly in WT (paired t-test, t8 = 6.953, p < 0.001) and 
YAC128 (t9 = 2.888, p = 0.018) cells (Figure 4B). The D2 agonist 
(quinpirole, 10 μM) similarly decreased NMDA current amplitudes 
in WT (t4 = 3.290, p = 0.03) and YAC128 (t4 = 4.103, p = 0.015) 
cells (Figure 4C).
loss of d1 ModulatIon Is reVersed BY da Blockers
We examined DA modulation in slices by testing the effect of the 
D1 agonist SKF81297 on sEPSC frequency at 1.5 months. While in 
D1-WT cells, SKF81297 increased sEPSC frequency (paired t-test: 
t20 = 5.867, p < 0.001), the D1 agonist did not have any effect on 
D1-YAC128 cells (t7 = 0.607, p = 0.563; Figures 5A,B). By contrast, 
at a later stage, the D1 agonist effect was similar in D1-WT and 
D1-YAC128 cells (André et al., 2011). This early alteration in DA 
neurotransmission might be induced by abnormal DA concen-
trations as we show that DA receptors are functional (Figure 4). 
p < 0.001) ms (Figures 3B,C) suggesting an increased probability 
of glutamate release onto cells of the direct pathway in BACHD 
mice at an early stage. D2-BACHD cells did not show any difference 
in PPRs compared to their WT littermates (two-way RM ANOVA 
F1,83 = 0.19, p = 0.662, Figure 3C), again similar to that finding in 
D2-YAC128 cells at the early stage.
At this early stage, we found similar increases in frequency of 
sIPSCs in D1-BACHD as we showed in D1-YAC128 cells with a 
significant leftward shift in cumulative probability histograms in 
the D1-BACHD cells suggesting increased probability of GABA 
release (Figure 3D). However, as the changes in mean sIPSC 
frequency did not reach significance in D1-BACHD compared 
to D1-WT cells (t23 = 1.736, p = 0.096, Figure 3D inset), the 
increase of GABA release might not be of the same amplitude 
in the BACHD mice as it was in the YAC128 mice, at least at 
the early stage. D2-BACHD cells did not show any differences 
in sIPSC mean frequency or in cumulative inter-event interval 
distribution (Figure 3E).
d1 and d2 receptors are stIll functIonal In Yac128
As EGFP was visible in YAC128 and WT cells and no difference 
in the intensity of fluorescence was observed (Figure 4A), we 
hypothesized that DA D1 and D2 receptors are still expressed in 
FiGure 1 | Alterations in excitatory and inhibitory transmission in 
D1-YAC128 cells. (A) Traces show sEPSCs in the presence of Bic in D1 cells 
from 1.5-month-old WT (left) and YAC128 (right) mice. (B) Graph shows that at 
1.5 months, mean sEPSC frequency is higher in D1-YAC128 cells (n = 9) 
compared to D1-WT (n = 31) while at 12 months, it is lower in D1-YAC128 cells 
(n = 15) than in D1-WT cells (n = 16). (C) There was a leftward shift in the 
cumulative probability distribution of inter-event intervals for sEPSCs in 
D1-YAC128 cells at 1.5 months, while at 12 months there was a rightward shift 
D1-YAC128 cells. (D) Traces show sIPSCs in D1 cells from 1.5-month-old WT 
(left) and YAC128 (right) mice. (e) Graph shows that mean sIPSC frequency at 
1.5 months is higher in D1-YAC128 (n = 20) than in D1-WT (n = 31) while at 
12 months, it is similar in D1-WT (n = 17) and D1-YAC128 cells (n = 14). (F) 
There was a leftward shift in the cumulative probability distribution of 
inter-event intervals for sIPSCs at 1.5 months, while at 12 months the 
distributions of sIPSC are similar. *, **: significant difference between WT and 
YAC128 cells.
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D1-WT cells, SCH23390 (10 and 20 μM) did not have a significant 
effect on sEPSC frequency. In contrast 20 μM SCH23390 signifi-
cantly decreased sEPSC frequency in D1-BACHD cells (t10 = 2.416, 
p = 0.036). The D1 antagonist effect was significantly different 
between WT and BACHD cells (t18 = 2.858, p = 0.01; Figure 5D, 
inset). SCH23390 (10 μM) did not significantly decrease sIPSC 
frequency in D1-WT cells although there was a trend (Figure 5E). 
In D1-BACHD cells, SCH23390 decreased sIPSC frequency by 
−36.3 ± 11.5% (t5 = 3.027, p = 0.029). However, the difference 
between D1-WT and D1-BACHD cells was not statistically differ-
ent (Figure 5E, inset).
dIscussIon
Visualization of direct and indirect pathway MSNs by EGFP 
expression allowed us to differentiate the two types of MSNs and 
to uncover alterations in the two pathways that differed with the 
progression of the disease. The use of mice expressing the reporter 
protein EGFP through a BAC transgene has proved to alter the 
expression of the D2 receptor, and induce electrophysiological 
hypersensitivity to D2 receptor agonists in midbrain DA neurons, 
as well as hyperactivity, suggesting the need for better tools to 
visualize D2 receptor-expressing neurons (Kramer et al., 2011). 
This characterization was mainly performed on homozygote BAC 
Previous studies showed that elevated striatal DA concentrations 
decrease DA receptor function (Giros et al., 1996; Dumartin et al., 
2000; Wu et al., 2007). In addition, decreasing DA concentrations 
with TBZ alleviates chorea in HD patients (Huntington Study 
Group, 2006). TBZ is a monoamine depleter, but it ultimately 
depletes DA stores (Pettibone et al., 1984), suggesting that decreas-
ing DA might be beneficial for hyperkinetic symptoms. To test 
whether DA function could be rescued in early HD, we examined 
the effect of TBZ and D1 antagonists in early HD.
In slices incubated in TBZ (10 μM) for at least 2 h, SKF81297 
significantly increased sEPSC frequency in D1-YAC128 cells 
(t8 = 2.672, p = 0.028), and its effect was similar to that of the D1 
agonist in D1-WT cells (Figures 5A,B). In D1-BACHD cells, pre-
incubation in TBZ also rescued the decrease in PPRs (Figure 5C). 
As TBZ was dissolved in DMSO, we tested the effect of DMSO alone 
on PPR in D1-BACHD cells. In the BACHD cells, DMSO had no 
effect on PPRs, indicating that the rescue effect was induced by TBZ. 
PPRs from TBZ-incubated slices in D1-BACHD cells were similar to 
those of D1-WT cells. To examine whether alterations in glutamate 
and GABA transmission could be induced by abnormally elevated 
activation of D1 receptors, we tested the effect of the D1 receptor 
antagonist SCH23390 (10 μM) on sEPSC and sIPSC frequency 
in D1-BACHD cells. SCH23390 was added after a stable baseline 
of sEPSCs or sIPSCs was established (in different cells), and the 
FiGure 2 | Alterations in excitatory and inhibitory transmission in 
D2-YAC128 cells. (A) Traces show sEPSCs in D2 cells from 1.5-month-old WT 
(left) and YAC128 (right) mice. (B) Graph shows there are no significant 
differences in mean EPSC frequency between D2-YAC128 (n = 25 at 1.5 and 
n = 13 at 12 months) and D2-WT (n = 14 at 1.5 and n = 20 at 12 months) cells at 
any age. (C) Cumulative probability distributions of inter-event interval 
histograms for sEPSCs show that D2-WT and D2-YAC128 cells display similar 
distributions at 1.5 months, while at 12 months D2-YAC128 cells display 
significantly fewer events at the longer intervals only. (D) Traces show sIPSCs in 
D2 cells from 1.5-month-old WT (left) and YAC128 (right) mice. (e) Graph shows 
that mean sIPSC frequency in D2 cells is similar in D2-WT (n = 26) and 
D2-YAC128 cells (n = 16) at 1.5 months while at 12 months, IPSC frequency is 
higher in D2-YAC128 (n = 14) than in D2-WT cells (n = 15). (F) Cumulative 
probability distributions of inter-event intervals for sIPSCs show that D2-YAC128 
cells display more events at 12 months but not at 1.5 months. *: significant 
difference between WT and YAC128 cells.
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direct pathway MSNs. Although we did not perform paired-pulse 
stimulation to measure PPRs for IPSCs in this particular study, our 
data on sIPSCs show that the frequency of GABA-mediated events 
is also higher onto direct pathway MSNs in YAC128 and BACHD 
mice. Furthermore, we have shown that PPRs of evoked IPSCs are 
decreased in MSNs in the R6/2 mouse, providing further evidence for 
the hypothesis of increased GABA release in HD (Rao et al., 2010). 
Taken together, our results suggest that both glutamate and GABA 
release are increased on direct pathway MSNs. Previously we dem-
onstrated that the frequency of sIPSCs increases in HD (Cepeda 
et al., 2004). The present study indicates that the increase is specific 
to D1-expressing neurons in the early stage.
D1 and D2 receptors are functionally active in acutely dissoci-
ated YAC128 cells while D1 and D2 receptors were not responsive 
in slices. The dissociated preparation isolates neurons from synaptic 
inputs and from ambient DA, while in slices neurons have active 
synapses and are exposed to modulators. As striatal neurotrans-
mitter release is modulated by DA receptors located on presyn-
aptic terminals and postsynaptically on the two types of MSNs, 
we hypothesized that abnormal DA transmission in slices could 
underlie differential alterations of excitatory and inhibitory trans-
mission onto direct and indirect pathway neurons. Our data show 
that blocking DA function with a D1 antagonist had larger effects in 
D1-BACHD cells than in WT cells and that depleting DA with TBZ 
decreased stereotypies in the BACHD model (André et al., 2011). 
These findings suggest that at an early stage, DA tone or basal func-
tion is increased and might contribute to some of the symptoms in 
HD by altering neuronal activity in the direct pathway. Our results 
are in line with observations that DA receptor antagonists and 
agents that decrease DA reduce chorea and motor symptoms in 
patients and in animal models while dopaminergic stimulation can 
exacerbate symptoms (Huntington Study Group, 2006; Tang et al., 
2007; Mestre et al., 2009). It is unclear why we did not observe any 
changes in GABA or glutamate transmission in D2 cells at the early 
stage. As DA induces reduction of neurotransmitter release onto D2 
cells via activation of pre and postsynaptic receptors (Kreitzer and 
Malenka, 2007; André et al., 2010), a decrease of neurotransmitter 
release could be expected in D2 cells at an early stage. However, 
in another study, an increased facilitation of evoked EPSCs was 
reported in 26-day-old YAC128. The authors suggested this could 
be interpreted as a decrease in the probability of glutamate release 
in indirect pathway MSNs (Milnerwood and Raymond, 2007). We 
could have missed those alterations onto indirect pathway MSNs 
since we performed our early stage recordings in slightly older mice 
between 45 and 60 days.
It is also unclear why changes in DA transmission would affect 
glutamate and GABA synaptic activity in D1 MSNs while having no 
effects in D2 MSNs, especially if considering that the proportion of 
high-affinity D2 receptors is much greater than the proportion of 
high-affinity D1 receptors in the striatum (Richfield et al., 1989). 
It is important to consider that DA influence also depends on the 
number of receptors within a sphere of DA spillover (Rice and 
Cragg, 2008). Although no study evaluated the number of high- 
and low-affinity DA receptors, it was reported that D1 receptors 
are in considerable excess of D2 receptors in the striatum (Richfield 
et al., 1989; Benn et al., 2007). It is therefore possible that in cases 
transgenic mice, and heterozygote mice might display a milder 
phenotype although the study also found some behavioral changes 
in heterozygote mice. In our study, we used heterozygote mice and 
we excluded all D2-EGFP mice for behavioral studies. Although 
we did not extensively compare EGFP-positive and negative MSNs, 
we found that the effect of the D2 agonist was decreased in HD 
mice, and that in early HD, most alterations were present in direct 
pathway MSNs, validating the use of EGFP to compare WT and 
HD mice.
GlutaMate transMIssIon and GaBa transMIssIon are 
Increased onto dIrect pathwaY neurons at the earlY staGe  
of hd
In both YAC128 and BACHD animal models, we observed an increase 
in sEPSC and in sIPSC frequency in D1 cells at an early symptomatic 
age. In addition, there was a decrease in PPRs for evoked glutamate 
responses (Table 1). Low PPRs at short intervals indicate depletion 
of neurotransmitter from the presynaptic terminal and an increased 
probability of release of the immediately releasable store (Zucker, 
1989; Choi and Lovinger, 1997). There were also increased frequencies 
of miniature EPSCs but no change in event amplitude (André et al., 
FiGure 3 | Glutamate and GABA transmission in BACHD mice at 
2 months. (A) Mean sEPSC frequency is increased in D1-BACHD cells 
(n = 11) compared to D1-WT cells (n = 9). (B) Traces of two evoked glutamate 
responses at 25 ms interval. (C) PPRs were significantly decreased in 
D1-BACHD cells (n = 10) compared to D1-WT cells (n = 8) at 2 months (25, 50, 
and 100 ms intervals), indicating increased probability of glutamate release. In 
D2 cells, PPRs were similar in WT (n = 11) and BACHD mice (n = 6). (D,e) 
Cumulative probability distributions of inter-event intervals for sIPSCs show 
that D1-BACHD (n = 14) cells display more events at shorter intervals than 
D1-WT cells (n = 11) at 1.5 months, while D2 cells show no differences in 
sIPSC distribution (WT, n = 6; BACHD, n = 6). Insets in (D,e) show mean 
sIPSC frequencies *: significant difference between WT and BACHD.
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1999; Patel et al., 2003). In late HD, a lack of DA or D2 receptors in 
indirect pathway MSNs could therefore increase GABA release onto 
indirect pathway MSN via a lack of endocannabinoid release. This 
effect will not occur in D1 cells, not expressing D2 receptors.
Decreased DA tone or DA function could also contribute to 
hyperexcitability of interneurons and increased GABA release 
(Dehorter et al., 2009). Our data showing a lack of effect of a D2 
antagonist in D2-YAC128 cells (André et al., 2011) support the 
hypothesis that DA function is decreased in late HD. In this case, 
one would also expect an increase of sIPSCs onto direct pathway 
MSNs, except if direct and indirect pathway MSNs are connected 
by different types of interneurons as suggested by a recent study 
(Gittis et al., 2010). In the case of abnormally low DA function, 
an increase in glutamate release would also be expected since DA 
D2 receptors are also present on presynaptic glutamate terminals 
and act to decrease neurotransmitter release when activated by DA 
(Wang and Pickel, 2002; Bamford et al., 2004). However, sEPSC 
frequency was not increased in the indirect pathway MSNs, and 
was even slightly decreased. This might be explained by the loss of 
corticostriatal inputs at this late stage of the disease.
functIonal consequences of alteratIons In dIrect and 
IndIrect pathwaY Msns
Increased probability of glutamate release onto D1 cells will shift the 
balance of direct and indirect pathway activity, disinhibiting output 
structures such as the colliculus and the thalamus, and   increasing 
of abnormal DA transmission, or DA spillover, D1 receptors are 
more affected than D2 receptors. Other factors such as differential 
glutamate cortical and GABAergic striatal inputs formed onto D1 
and D2 MSNs (Lei et al., 2004; Kreitzer and Malenka, 2006; Cepeda 
et al., 2008; Gittis et al., 2010) could also contribute to prominent 
changes in D1 MSNs in early HD.
GlutaMate transMIssIon Is decreased onto all Msns at a late 
staGe whIle GaBa transMIssIon Is Increased onto IndIrect 
pathwaY Msns
The fact that glutamate transmission is decreased onto both direct and 
indirect pathway MSNs is consistent with a progressive disconnection 
between cortex and striatum (Cepeda et al., 2003). However, this effect 
was more marked onto direct pathway MSNs, showing both decreased 
sEPSC frequency and increased PPRs, while indirect pathway MSNs 
showed only a subtle decrease of sEPSCs (Figure 6). In contrast to glu-
tamate transmission, GABA transmission was increased onto indirect 
pathway MSNs, suggesting that unlike glutamate terminals, GABA 
terminals might not disconnect in the YAC128 model. In the R6/2 
model, we have provided evidence that the increased GABA transmis-
sion emanates from GABAergic interneurons that may be hyperexcit-
able (Rao et al., 2010). The fact that increased inhibition was observed 
only onto indirect pathway MSNs indicates that cannabinoid signaling 
might be involved. Cannabinoid type 1 (CB1) receptors are located on 
striatal GABAergic terminals, inhibiting GABA release when activated 
(Szabo et al., 1998; Kofalvi et al., 2005). Endogenous ligands for the 
cannabinoid receptors are released by MSNs via activation of DA D2 
FiGure 4 | D1 and D2 receptor modulation in acutely dissociated MSNs is 
similar in WT and YAC128 cells at 1.5 months. (A) Examples of acutely 
dissociated MSNs in WT and YAC128. (B) Traces of NMDA currents (100 μM) in 
D1 cells show the D1 agonist SKF81297 (1 μM) increases the amplitude of 
NMDA currents in D1-WT (n = 9) and D1-YAC128 cells (n = 10). Graph shows the 
percent potentiation by SKF81297 is similar in D1-WT and D1-YAC128 cells. (C) 
Traces of NMDA currents (100 μM) in D2 cells show the D2 agonist quinpirole 
(10 μM) decreases NMDA currents in D2-WT (n = 5) and D2-YAC128 cells 
(n = 5). Graph shows the percent attenuation by quinpirole is similar in D2-WT 
and D2-YAC128 cells.
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in young BACHD and YAC128 mice might be induced by overactiva-
tion of D1 cells as has been observed in cases of elevated DA transmis-
sion (Usiello et al., 2000; Horvitz et al., 2001). Although hypoactivity 
in symptomatic HD animals has been reported, there is evidence that 
hyperactivity and stereotyped behaviors occur in lesion models in rats 
(Borlongan et al., 1997; Brouillet et al., 1999; Bolivar et al., 2004) and 
in early stage in transgenic mouse models carrying a short fragment 
or the full length of the human gene in different strains (Sanberg 
et al., 1989; Carter et al., 1999; Bolivar et al., 2004; Van Raamsdonk 
et al., 2005, 2007). Abnormal involuntary movements, dyskinesia and 
chorea are hallmarks of human pathology at early stages and the 
hyperkinetic syndrome is progressively replaced by a more hypoki-
netic syndrome (Thompson et al., 1988). In contrast, a decrease in the 
activity of direct pathway MSNs could explain the decreased locomo-
tor activity observed in the late symptomatic YAC128 mice.
The resulting effect of increased GABA release could also alter 
direct and indirect pathway activity. The effect of GABAA receptor 
activation on striatal cell excitability depends on the cell membrane 
potential as the reversal potential for Cl− is ∼−60 mV and the  resting 
membrane potential for MSNs is hyperpolarized (∼ −80 to −90 mV). 
FiGure 5 | Alterations in DA modulation in early HD. (A) Traces of sEPSCs in 
a D1-WT MSN (left), a D1-YAC128 MSN (middle) and a TBZ-treated D1-YAC128 
MSN before and after application of the D1 agonist SKF81297 at 1.5 months. 
(B) Bar graph shows that the D1 agonist increased sEPSC frequency in D1-WT 
cells (n = 12) while it had no effect in D1-YAC128 cells (n = 10). The D1 agonist 
effect on sEPSC frequency was restored by TBZ treatment in D1-YAC128 cells 
(n = 8). (C) Top panel shows traces of paired-pulse evoked glutamate currents in 
D1-BACHD cells at 2 months. Bottom panel graph shows the decrease in PPRs 
in DMSO-treated D1-BACHD cells (n = 17) is increased in TBZ-treated 
D1-BACHD cells (n = 8). (D) Amplitude–frequency histogram shows that in 
D1-WT cells, the D1 antagonist SCH23390 (20 μM) had no effect on sEPSC 
frequency. In contrast, in D1-BACHD cells (2 months), the D1 antagonist 
decreased sEPSC frequency. Inset shows that the percent change induced by 
SCH23390 is significantly different in D1-WT (n = 9) and D1-BACHD cells 
(n = 11). (e) Amplitude–frequency histogram shows that in D1-WT cells (n = 8), 
the D1 antagonist SCH23390 (10 μM) did not significantly decrease the 
frequency of sIPSCs. In D1-BACHD cells (n = 6), the D1 antagonist decreased 
the frequency of sIPSCs. Inset shows that although the percent change induced 
by SCH23390 tended to be higher in D1-BACHD cells, it was not significantly 
different from that in D1-WT cells. *p < 0.05, **p < 0.01, effect of TBZ or 
SCH23390 compared to control; #p < 0.05 and ###p < 0.001, difference 
between WT and YAC128 or BACHD cells.
In vivo, MSN membrane potentials oscillate between hyperpolarized 
“down” and more depolarized “up” states (Wilson and Kawaguchi, 
1996). Therefore, activation of GABAA   receptors depolarizes MSN 
membrane at rest while it hyperpolarizes membrane potential near 
the action potential threshold (Mercuri et al., 1991; Koos and Tepper, 
1999). Although our results in current-clamp show there are no 
changes in membrane excitability in YAC128 cells at the early stage 
(André et al., 2011), more data are needed to determine the conse-
quences of increased GABA on MSN activity.
conclusIon
The present findings suggest anomalies in glutamate and GABA 
transmission in HD might be induced by abnormal DA transmis-
sion. Early in the progression of the disease, increased glutamate 
release onto D1 cells and increased stereotypies are consistent 
with increased DA tone (Presti et al., 2004). In symptomatic ani-
mals, decreased glutamate release onto D1 cells and hypoactive 
behavior are consistent with decreased DA tone and/or loss of 
corticostriatal terminals. Our data suggest that modulation of 
direct pathway neurons with D1 antagonists or agents decreasing 
DA function in early HD stage might prove useful as a strategy 
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to treat   hyperkinetic motor symptoms. In contrast, DA agonists 
at more advanced stages might prove useful as a strategy to treat 
hypokinetic motor symptoms. In the future, studies are necessary 
to understand the consequences of altered GABA and glutamate 
Table 1 | Summary of changes in spontaneous excitatory and inhibitory 
currents and dopamine modulation in D1 and D2 cells in early and late 
stage HD in the YAC128 and BACHD models.
  early HD  Late HD
  D1 MSNs  D2 MSNs  D1 MSNs  D2 MSNs
YAC128
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  Dopamine modulation of EPSC frequency in slices
    D1 agonist  No effect    Normal 
    D2 agonist    No effect    No effect
  Dopamine modulation of NMDA currents in isolated neurons
    D1 agonist  Normal    Not tested
  D2  agonist    Normal 
BACHD 
  PPR glut  ↓ – 
  EPSC frequency  ↑ – 
  IPSC frequency  ↑ – 
↓Decrease compared to WT.
↑Increase compared to WT.
–No change compared to WT.
FiGure 6 | representation of glutamate, GABA, and DA projections onto 
direct (D1) and indirect pathway (D2) MSNs in HD. In WT (left), DA released 
by nigrostriatal inputs activates glutamate and GABA release onto D1 MSNs 
while it decreases glutamate and GABA release onto D2 MSNs. In early HD 
(middle), increased DA transmission leads to increased release of glutamate 
and GABA onto D1 MSNs. There is no change onto D2 MSNs, suggesting 
changes in indirect pathway MSNs might occur at a different time point or 
involve other mechanisms. In late HD (right), D1 MSNs display decreases in 
glutamate transmission, presumably due to loss of corticostriatal inputs and/
or decreased DA transmission. In contrast, D2 MSNs display only a small 
decrease in glutamate synaptic inputs while GABA synaptic transmission is 
increased, probably through altered D2 receptor function.
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